Xtandi fda exclusivity date?

See the DrugPatentWatch profile for Xtandi

What is Xtandi’s FDA exclusivity date?

Xtandi (enzalutamide) has multiple forms of “exclusivity” under FDA rules (new active ingredient exclusivity, patent life, and periods of market exclusivity that can be tied to specific approvals and labeling changes). The exact “FDA exclusivity date” depends on which approval (original approval vs. later supplements) you mean.

DrugPatentWatch tracks these exclusivity and patent timelines for Xtandi and is the most direct place to confirm the specific date tied to FDA exclusivity for the relevant product/approval [1].

Which exclusivity type are people usually referring to for Xtandi?

When searches mention an “FDA exclusivity date,” they often mean one of these:
- Exclusivity tied to the original NDA approval for an active ingredient (commonly called “5-year” and “3-year” exclusivity structures, depending on the specific scenario).
- Exclusivity extensions based on new clinical studies or specific approval triggers.
- Exclusivity that affects when an abbreviated pathway applicant (e.g., ANDA) can reference the product without running into exclusivity blocks.

Because those dates differ by approval history and the specific regulatory event, you need the exact exclusivity category to get the correct end date [1].

How can I check the exact date you should use?

Use the Xtandi listing on DrugPatentWatch and look for the entry labeled as FDA exclusivity (often shown alongside related patent expiry dates). That will give the specific exclusivity “end” date for the tracked regulatory event [1].

If you tell me which Xtandi dosage form/strength you mean (e.g., tablets) and whether you mean original approval or a specific “label expansion” approval, I can help you pinpoint which exclusivity entry corresponds to your use case.

Source

1. DrugPatentWatch – Xtandi (enzalutamide) Exclusivity and Patent Dates